Matches in SemOpenAlex for { <https://semopenalex.org/work/W2552453118> ?p ?o ?g. }
- W2552453118 abstract "Direct-acting antivirals (DAA) for the treatment of hepatitis C virus (HCV) have drastically improved outcomes but are also very costly. For this reason, priority for treatment is often given to patients with a higher fibrosis score at baseline by payers and providers rather than treating all eligible patients. Simulation studies have suggested that waiting to treat patients until fibrosis 3-4 may be more costly and result in worse outcomes; however, real-world implications are unknown.To determine drug costs and outcomes for treating hepatitis C in patients with fibrosis scores of 0-2 and 3-4 at baseline in a real-world ambulatory care setting.A total of 322 patients at 36 clinical sites in Massachusetts with HCV genotype 1-4 and a prescription for at least 1 DAA medication between May 2011 and October 2015 were included. Retrospective and prospective chart reviews were completed by the primary investigator. Data were collected through April 2016. The primary outcome for the study was to determine the mean drug cost per sustained virologic response (SVR) achieved for patients with fibrosis scores of 0-2 and 3-4. Drug costs were calculated using average wholesale price and only included the cost of HCV medications, not for adjunctive medications, blood work, hospitalizations, anticipated complications, or any other projected medical costs.The mean ± SD (median) drug cost per patient was $130,391 ± 46,787 (113,400) and completed treatment duration was 15.0 ± 8.9 (12) weeks. The mean drug cost per SVR was $155,662 for all patients with a mean drug cost per SVR of $122,452 and $178,401 for patients with fibrosis scores of 0-2 and 3-4, respectively. SVR rates were 83.5% (269/322) for all patients and 92.2% (107/116) and 78.6% (162/206) for patients with fibrosis scores of 0-2 and 3-4, respectively. Ledipasvir/ sofosbuvir; sofosbuvir + ribavirin; ledipasvir/sofosbuvir + ribavirin; sofos-buvir + interferon + ribavirin; boceprevir + interferon + ribavirin; sofosbu-vir + simeprevir; and telaprevir + interferon + ribavirin had a mean drug cost per SVR of $123,559; $153,347; $157,969; $184,800; $248,640; $251,550; and $373,333; respectively.Real-world knowledge about outcomes and drug costs may influence future decisions. Further studies are needed to evaluate emerging treatment options and to reflect changes in treatment guidelines.No outside funding supported this study. The authors report no conflicts of interest. Data in this study were presented as a poster at the ASHP Midyear Clinical Meeting; New Orleans, Louisiana; December 9, 2015; at the Massachusetts Society of Health-System Pharmacists Annual Meeting; Newton, Massachusetts; April 12, 2016; and at Eastern States Conference for Pharmacy Residents and Preceptors; Hershey, Pennsylvania; May 2, 2016. Study concept and design was primarily contributed by Bach, along with Zaiken. Bach took the lead in data collection, data interpretation, and preparation of the manuscript, along with Zaiken." @default.
- W2552453118 created "2016-11-30" @default.
- W2552453118 creator A5053408947 @default.
- W2552453118 creator A5072618581 @default.
- W2552453118 date "2016-12-01" @default.
- W2552453118 modified "2023-09-25" @default.
- W2552453118 title "Real-World Drug Costs of Treating Hepatitis C Genotypes 1-4 with Direct-Acting Antivirals: Initiating Treatment at Fibrosis 0-2 and 3-4" @default.
- W2552453118 cites W1571790880 @default.
- W2552453118 cites W1826923552 @default.
- W2552453118 cites W1934982766 @default.
- W2552453118 cites W1953390113 @default.
- W2552453118 cites W1966643018 @default.
- W2552453118 cites W1971991764 @default.
- W2552453118 cites W1973675889 @default.
- W2552453118 cites W1980154502 @default.
- W2552453118 cites W1982344292 @default.
- W2552453118 cites W1986242361 @default.
- W2552453118 cites W1986725099 @default.
- W2552453118 cites W2002557123 @default.
- W2552453118 cites W2010077001 @default.
- W2552453118 cites W2012888889 @default.
- W2552453118 cites W2015763165 @default.
- W2552453118 cites W2018460596 @default.
- W2552453118 cites W2026809179 @default.
- W2552453118 cites W2036913245 @default.
- W2552453118 cites W2043193067 @default.
- W2552453118 cites W2045245188 @default.
- W2552453118 cites W2078251659 @default.
- W2552453118 cites W2078799829 @default.
- W2552453118 cites W2081897332 @default.
- W2552453118 cites W2088567273 @default.
- W2552453118 cites W2092646281 @default.
- W2552453118 cites W2095348495 @default.
- W2552453118 cites W2111335059 @default.
- W2552453118 cites W2113428683 @default.
- W2552453118 cites W2114757306 @default.
- W2552453118 cites W2120733999 @default.
- W2552453118 cites W2123251487 @default.
- W2552453118 cites W2127548135 @default.
- W2552453118 cites W2145409766 @default.
- W2552453118 cites W2150652264 @default.
- W2552453118 cites W2151554611 @default.
- W2552453118 cites W2163732694 @default.
- W2552453118 cites W2178511310 @default.
- W2552453118 cites W2179707291 @default.
- W2552453118 cites W2290229326 @default.
- W2552453118 cites W2310812194 @default.
- W2552453118 cites W2339382141 @default.
- W2552453118 cites W2344591610 @default.
- W2552453118 cites W2585248534 @default.
- W2552453118 doi "https://doi.org/10.18553/jmcp.2016.22.12.1437" @default.
- W2552453118 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27882839" @default.
- W2552453118 hasPublicationYear "2016" @default.
- W2552453118 type Work @default.
- W2552453118 sameAs 2552453118 @default.
- W2552453118 citedByCount "4" @default.
- W2552453118 countsByYear W25524531182017 @default.
- W2552453118 countsByYear W25524531182018 @default.
- W2552453118 countsByYear W25524531182019 @default.
- W2552453118 crossrefType "journal-article" @default.
- W2552453118 hasAuthorship W2552453118A5053408947 @default.
- W2552453118 hasAuthorship W2552453118A5072618581 @default.
- W2552453118 hasBestOaLocation W25524531181 @default.
- W2552453118 hasConcept C126322002 @default.
- W2552453118 hasConcept C167135981 @default.
- W2552453118 hasConcept C177713679 @default.
- W2552453118 hasConcept C194828623 @default.
- W2552453118 hasConcept C203014093 @default.
- W2552453118 hasConcept C2426938 @default.
- W2552453118 hasConcept C2522874641 @default.
- W2552453118 hasConcept C2776408679 @default.
- W2552453118 hasConcept C2776455275 @default.
- W2552453118 hasConcept C71924100 @default.
- W2552453118 hasConcept C98274493 @default.
- W2552453118 hasConceptScore W2552453118C126322002 @default.
- W2552453118 hasConceptScore W2552453118C167135981 @default.
- W2552453118 hasConceptScore W2552453118C177713679 @default.
- W2552453118 hasConceptScore W2552453118C194828623 @default.
- W2552453118 hasConceptScore W2552453118C203014093 @default.
- W2552453118 hasConceptScore W2552453118C2426938 @default.
- W2552453118 hasConceptScore W2552453118C2522874641 @default.
- W2552453118 hasConceptScore W2552453118C2776408679 @default.
- W2552453118 hasConceptScore W2552453118C2776455275 @default.
- W2552453118 hasConceptScore W2552453118C71924100 @default.
- W2552453118 hasConceptScore W2552453118C98274493 @default.
- W2552453118 hasLocation W25524531181 @default.
- W2552453118 hasLocation W25524531182 @default.
- W2552453118 hasOpenAccess W2552453118 @default.
- W2552453118 hasPrimaryLocation W25524531181 @default.
- W2552453118 hasRelatedWork W2002091096 @default.
- W2552453118 hasRelatedWork W2105151527 @default.
- W2552453118 hasRelatedWork W2898975403 @default.
- W2552453118 hasRelatedWork W2951130915 @default.
- W2552453118 hasRelatedWork W3009852707 @default.
- W2552453118 hasRelatedWork W3013145321 @default.
- W2552453118 hasRelatedWork W3208090289 @default.
- W2552453118 hasRelatedWork W3210359220 @default.
- W2552453118 hasRelatedWork W4205529031 @default.
- W2552453118 hasRelatedWork W4255376461 @default.
- W2552453118 isParatext "false" @default.